Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
3.170
-0.250 (-7.31%)
Mar 31, 2025, 1:02 PM EDT - Market open
Company Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
The company’s lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis.
It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Galecto, Inc.
| Country | Denmark |
| Founded | 2011 |
| IPO Date | Oct 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Hans Schambye |
Contact Details
Address: Ole Maaloes Vej 3, Copenhagen N Copenhagen, 2200 Denmark | |
| Phone | 45 70 70 52 10 |
| Website | galecto.com |
Stock Details
| Ticker Symbol | GLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001800315 |
| CUSIP Number | 36322Q107 |
| ISIN Number | US36322Q1076 |
| Employer ID | 37-1957007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Garrett Winslow Esq. | Senior Vice President, General Counsel and Corporate Secretary |
| Ulf J. Nilsson Ph.D. | Co-Founder |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
| Lori C. Firmani | Interim Chief Financial Officer |
| Matthew Kronmiller | Executive Vice President of Strategy and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2025 | 10-K | Annual Report |
| Jan 16, 2025 | SCHEDULE 13D/A | Filing |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | 10-Q | Quarterly Report |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |